Kivo keeps a pretty low profile. Even though they are composed of a number of experienced alums from the Portland startup community. Which is likely the reason that investors have decided to invest $5.1 million more into the company.
“We sell pretty extensively to regulatory groups that manage the interaction with the FDA, clinical groups that run the clinical trials, and quality groups that manage the overall process of all of that plus manufacturing the drug,” CEO Toban Zolman told the Portland Business Journal.
This round was led by Hatteras Venture Partners and Grayhawk Capital. Also participating were existing investors Oregon Venture Fund, Cascade Seed Fund, Rogue Venture Partners and Peninsula Ventures.
The decision to raise another round came from both company leadership and investors, Zolman said. Existing investors were the lead on pulling together the term sheet and brought in the new investors. The process started last summer and wrapped just before the end of the year, he said.
For more, visit Kivo.
